Wave Life Sciences Ltd. announced new preclinical and early clinical data supporting its investigational therapeutic WVE-007, a GalNAc-siRNA targeting INHBE for the treatment of obesity. Preclinical results, which will be presented at ObesityWeek® 2025, indicate that WVE-007 may reduce fat while preserving muscle mass and could be administered once or twice per year. In animal models, the therapy led to adipocyte shrinkage, reduced inflammation and fibrosis, and improved insulin sensitivity. Additionally, WVE-007 enhanced weight loss when used in combination with semaglutide and prevented weight regain after semaglutide cessation. In the ongoing INLIGHT first-in-human clinical trial, WVE-007 demonstrated dose-dependent and significant reductions in Activin E levels at one month post-dose across multiple cohorts, with reductions exceeding those necessary for weight loss in preclinical studies. Reductions were sustained for six months in the lowest dose cohort. WVE-007 was reported to be safe and well-tolerated to date, and dose escalation is ongoing. Wave Life Sciences plans to release additional clinical data, including body composition and weight outcomes, starting in the fourth quarter of 2025 and continuing into 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wave Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568953-en) on November 05, 2025, and is solely responsible for the information contained therein.
Comments